The three main GH-pathway profiles

The body-composition and GH-pathway category is not a single product class. Buyers commonly encounter three distinct mechanism profiles:

  • GHRH analogues such as Tesamorelin, which act on the growth-hormone-releasing-hormone pathway.
  • Ghrelin-receptor agonists / secretagogues such as Ipamorelin, which act through the GHS-R pathway.
  • No-DAC presentations such as CJC-1295 (No DAC), distinguished from longer-acting DAC formulations.

Why the distinction matters commercially

Different customer segments respond to different mechanism narratives. A clinic or wellness buyer may prefer well-recognised GHRH analogue language; a performance or research-oriented buyer may look for secretagogue or no-DAC specificity. Positioning the products accurately reduces enquiry friction and supports repeat orders.

Strengths and SKUs in this category

  • Tesamorelin: 10 mg
  • Ipamorelin: 5 mg
  • CJC-1295 (No DAC): 2 mg

Documentation and verification

Before finalising any GH-pathway product order, verify the sequence, molecular weight, and current batch documentation with the supplier. CJC-1295 (No DAC) and similar products can have naming variations across the market, so SKU clarity is essential.